NASA One Year After Challenger

SAN FRANCISCO—One year ago the U.S. space program came to an abrupt and shocking halt. As the remains of the Space Shuttle Challenger plummeted into the sea, an already tenuous and drifting Space and Earth Science Program reeled under the shock wave. While NASA says none of its 22,800 employees worldwide have been laid off, the scientific programs, both at NASA facilities and elsewhere, have unquestionably been affected severely. Previous decisions to stretch out and delay flight projects

| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

While NASA says none of its 22,800 employees worldwide have been laid off, the scientific programs, both at NASA facilities and elsewhere, have unquestionably been affected severely. Previous decisions to stretch out and delay flight projects threaten to shatter an already shaky budget. Prior to the Challenger loss, 50 science flights were planned for the period 1986-1992. Now only 17 are scheduled, with an average delay of more than three years each. The delays will cost more than $1 billion—money which will come from an annual budget of only $1.5 billion.

Can NASA's Space and Earth Science program survive in the post-Challenger era? In five interviews by freelance writers Ray Spangenburg and Diane Moser, beginning on page 4, NASA scientists chosen for their diversity of location, experience and area of investigation reveal an uneasily shifting mood of hope and frustration, optimism and despair.

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies